TABLE 3.
Rates of represcriptions and hospitalizations within 28 days by antibiotic received and susceptibility
| Antibiotic class or resistance type | No. (%) of episodes (n = 5,395) | % (no.) of episodes with nonsusceptible isolates (n = 5,395) | No. of represcriptions/total no. of episodes (%) |
% difference (95% CI) | No. of hospitalizations/total no. of episodes (%)b |
% difference (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
| Susceptible | Nonsusceptiblea | Susceptible | Nonsusceptible | |||||
| Fluoroquinolone | 1,873 (34.7) | 22.8 (1,232) | 237/1,483 (16.0) | 140/390 (35.9) | −19.9 (−25.1, −15.0) | 130/1,483 (8.8) | 65/390 (16.7) | −7.9 (−12.2, −4.2) |
| β-Lactamc | 1,309 (24.3) | 25.1 (329) | ||||||
| ESBLd | 6.6 (356) | 224/980 (22.9) | 91/329 (27.7) | −4.8 (−10.5, 0.5) | 81/980 (8.3) | 48/329 (14.6) | −6.3 (−10.8, −2.4) | |
| Trimethoprim-sulfamethoxazole | 1,041 (19.3) | 27.6 (1,491) | 134/753 (17.8) | 106/288 (36.8) | −19.0 (−25.3, −13) | 71/753 (9.4) | 45/288 (15.6) | −6.2 (−11.2, −1.8) |
| Nitrofurantoin | 1,228 (22.8) | 15.9 (857) | 214/1,055 (20.3) | 64/173 (37.0) | −16.7 (−24.5, −9.4) | 73/1,055 (6.9) | 23/173 (13.3) | −6.4 (−12.4, −1.8) |
| Fosfomycin | NAe | NA | 0/1 (0.0) | 0/1 (0.0) | ||||
a
Intermediate or resistant.
b
Hospitalization data were available for 5,395 UTI episodes.
c
The number of episodes nonsusceptible to a β-lactam out of those that with an initial β-lactam prescription filled was 329 out of 1,309.
d
Isolates were confirmed as ESBL positive by commercial panels or were determined to be intermediate/resistant to an extended-spectrum cephalosporins (ceftriaxone, cefotaxime, ceftazidime, or cefepime).
e
NA, not applicable.